Skip to main content
Top
Published in: Heart and Vessels 3/2020

01-03-2020 | Edoxaban | Original Article

Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7)

Authors: Shinya Suzuki, Yoshiyuki Morishima, Atsushi Takita, Takayuki Otsuka, Naoharu Yagi, Takuto Arita, Takeshi Yamashita

Published in: Heart and Vessels | Issue 3/2020

Login to get access

Abstract

Direct oral anticoagulants, including edoxaban, primarily do not need routine monitoring of the anticoagulant effect. However, extremely high/low plasma concentrations of edoxaban (PC-Ed) should be properly evaluated, especially when patients under anticoagulation therapy are at an emergency state. For this purpose, PC-Ed determined by an anti-Xa assay (indirect PC-Ed) is more convenient and, therefore, more useful compared with PC-Ed determined by an LC–MS/MS (direct PC-Ed) in daily clinical practice. Consecutive 97 patients with non-valvular atrial fibrillation (NVAF) under edoxaban therapy were evaluated, in whom edoxaban 60/30 mg doses were prescribed for 48/49 patients, 71 (73.2%) were men, and the average age was 69 years. CHADS2 score 0, 1, and ≥ 2 were 26.8%, 44.3%, and 28.9%, while CHA2DS2-VASc score 0, 1, and ≥ 2 were 14.4%, 16.5%, and 69.1%, respectively. Median values of direct and indirect PC-Ed by LC–MS/MS and anti-Xa assay were 187.1 and 176.1 ng/mL at peak (2–4 h post-dose) and 14.4 and 17.5 ng/mL at trough (pre-dose), respectively. The PC-Ed at peak and trough by two methods were significantly correlated, and the correlation coefficients were r = 0.973 and 0.963 (both, p < 0.0001), respectively. By a Bland–Altman plot, mean differences between the direct and indirect PC-Ed [lower to upper percent limit of agreement] were − 4.87 [− 46.71 to 36.98] and 4.66 [− 1.37 to 10.69] ng/mL at peak and trough, respectively. Moreover, mean % error for difference between the direct and indirect PC-Ed [lower to upper percent limit of agreement] was − 1.22 [− 20.59 to 18.14] and 31.75 [− 14.03 to 77.53] % at peak and trough, respectively, where the % error extremely increased around the lower limit of detection (LLOD) in the anti-Xa assay. Strong similarity was observed between the direct and indirect PC-Ed, especially at peak. The indirect PC-Ed was higher than the direct PC-Ed, especially around the LLOD, suggesting the need for caution when we use the anti-Xa assay for measurement of trough PC-Ed (UMIN 000032492).
Literature
1.
go back to reference Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542–1549CrossRefPubMed Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542–1549CrossRefPubMed
2.
go back to reference Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288–2295CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288–2295CrossRefPubMed
3.
go back to reference Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294CrossRefPubMedPubMedCentral Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294CrossRefPubMedPubMedCentral
4.
go back to reference Douxfils J, Chatelain B, Chatelain C, Dogne JM, Mullier F (2016) Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 115:368–381CrossRefPubMed Douxfils J, Chatelain B, Chatelain C, Dogne JM, Mullier F (2016) Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 115:368–381CrossRefPubMed
5.
go back to reference Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRefPubMed Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRefPubMed
6.
go back to reference Cuker A (2016) Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 41:241–247CrossRefPubMed Cuker A (2016) Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 41:241–247CrossRefPubMed
7.
go back to reference Kodani E, Okumura K, Inoue H, Yamashita T, Atarashi H, Origasa H (2011) Present status and problems of international sensitivity index (ISI) on the measurement of international normalized ratio of prothrombin time (INR). Jpn J Electrocardiol 31:225–233CrossRef Kodani E, Okumura K, Inoue H, Yamashita T, Atarashi H, Origasa H (2011) Present status and problems of international sensitivity index (ISI) on the measurement of international normalized ratio of prothrombin time (INR). Jpn J Electrocardiol 31:225–233CrossRef
8.
go back to reference Suzuki S, Morishima Y, Takita A, Yagi N, Otsuka T, Arita T, Yamashita T (2019) Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7). Heart Vessels. https://doi.org/10.1007/s00380-019-01438-6CrossRefPubMed Suzuki S, Morishima Y, Takita A, Yagi N, Otsuka T, Arita T, Yamashita T (2019) Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7). Heart Vessels. https://​doi.​org/​10.​1007/​s00380-019-01438-6CrossRefPubMed
10.
go back to reference Akao M, Yamashita T, Okumura K, J-ELDAF Investigators (2016) Study design of J-ELD AF: a multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. J Cardiol 68:554–558CrossRefPubMed Akao M, Yamashita T, Okumura K, J-ELDAF Investigators (2016) Study design of J-ELD AF: a multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. J Cardiol 68:554–558CrossRefPubMed
12.
go back to reference Suzuki S, Yamashita T, Kasai H, Otsuka T, Sagara K (2017) Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of 5 representative reagents in Japan (CVI ARO 1). Thromb Res 150:73–75CrossRefPubMed Suzuki S, Yamashita T, Kasai H, Otsuka T, Sagara K (2017) Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of 5 representative reagents in Japan (CVI ARO 1). Thromb Res 150:73–75CrossRefPubMed
13.
go back to reference Suzuki S, Yamashita T, Kasai H, Otsuka T, Sagara K (2018) An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metab Pharmacokinet 33:188–193CrossRefPubMed Suzuki S, Yamashita T, Kasai H, Otsuka T, Sagara K (2018) An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metab Pharmacokinet 33:188–193CrossRefPubMed
19.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
20.
go back to reference Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 40:2250–2255CrossRefPubMed Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 40:2250–2255CrossRefPubMed
21.
go back to reference He L, Kochan J, Lin M, Vandell A, Brown K, Depasse F (2017) Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. Thromb Res 155:121–127CrossRefPubMed He L, Kochan J, Lin M, Vandell A, Brown K, Depasse F (2017) Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. Thromb Res 155:121–127CrossRefPubMed
22.
go back to reference Altman DG, Bland JM (1983) Measurement in Medicine: The Analysis of Method Comparison Studies. Statistician 32:307–317CrossRef Altman DG, Bland JM (1983) Measurement in Medicine: The Analysis of Method Comparison Studies. Statistician 32:307–317CrossRef
23.
go back to reference Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, Mullier F (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731CrossRefPubMed Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, Mullier F (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731CrossRefPubMed
24.
go back to reference Konigsbrugge O, Quehenberger P, Belik S, Weigel G, Seger C, Griesmacher A, Pabinger I, Ay C (2015) Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Ann Hematol 94:1463–1471CrossRefPubMed Konigsbrugge O, Quehenberger P, Belik S, Weigel G, Seger C, Griesmacher A, Pabinger I, Ay C (2015) Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Ann Hematol 94:1463–1471CrossRefPubMed
25.
go back to reference Studt JD, Alberio L, Angelillo-Scherrer A, Asmis LM, Fontana P, Korte W, Mendez A, Schmid P, Stricker H, Tsakiris DA, Wuillemin WA, Nagler M (2017) Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. J Thromb Haemost 15:1576–1583CrossRefPubMed Studt JD, Alberio L, Angelillo-Scherrer A, Asmis LM, Fontana P, Korte W, Mendez A, Schmid P, Stricker H, Tsakiris DA, Wuillemin WA, Nagler M (2017) Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. J Thromb Haemost 15:1576–1583CrossRefPubMed
26.
go back to reference Gosselin RC, Adcock Funk DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, Moll S (2014) Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 138:1680–1684CrossRefPubMed Gosselin RC, Adcock Funk DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, Moll S (2014) Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 138:1680–1684CrossRefPubMed
Metadata
Title
Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7)
Authors
Shinya Suzuki
Yoshiyuki Morishima
Atsushi Takita
Takayuki Otsuka
Naoharu Yagi
Takuto Arita
Takeshi Yamashita
Publication date
01-03-2020
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 3/2020
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-019-01501-2

Other articles of this Issue 3/2020

Heart and Vessels 3/2020 Go to the issue